Silver Spring’s United Therapeutics Corp. (NASDAQ: UTHR) set another revenue record in the third quarter — and with that momentum, is now homing in on its goal to more than double the number of patients currently using its therapies in the next couple of years. For the local biotech, which reported third-quarter earnings Wednesday, growing its patient count from its current 12,000 to 25,000 by 2025 requires “maintaining even half our current growth rate for the next three years,” which seems “eminently doable,” CEO Martine Rothblatt said on a company earnings call Wednesday.
United Therapeutics still eyeing 25K patients by 2025. Here’s what it’ll take to get there.
November 3, 2022